Aclaris Therapeutics Inc (ACRS) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.20x
Aclaris Therapeutics Inc (ACRS) has a Cash Flow-to-Debt Ratio of -0.20x as of September 2025, meaning its operating cash flow of $-10.93 Million could theoretically repay 0% of its total liabilities ($55.43 Million) in one year. See Aclaris Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.20x
Operating CF / Total Liabilities
Operating Cash Flow
$-10.93 Million
USD
Total Liabilities
$55.43 Million
USD
Data as of
Sep 2025
Most recent filing
Aclaris Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aclaris Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see Aclaris Therapeutics Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Aclaris Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Aclaris Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-20.07 Million | $64.77 Million | ▲ +84.1% |
| 2023 | -1.95x | $-78.33 Million | $40.23 Million | ▼ -64.2% |
| 2022 | -1.19x | $-67.57 Million | $56.98 Million | ▼ -22.5% |
| 2021 | -0.97x | $-52.13 Million | $53.87 Million | ▲ +17.0% |
| 2020 | -1.17x | $-38.63 Million | $33.13 Million | ▲ +65.7% |
| 2019 | -3.40x | $-96.44 Million | $28.39 Million | ▼ -103.7% |
| 2018 | -1.67x | $-100.81 Million | $60.44 Million | ▲ +44.3% |
| 2017 | -3.00x | $-54.66 Million | $18.25 Million | ▲ +42.9% |
| 2016 | -5.25x | $-34.60 Million | $6.59 Million | ▲ +59.9% |
| 2015 | -13.10x | $-20.37 Million | $1.55 Million | ▼ -6441.3% |
| 2014 | -0.20x | $-7.64 Million | $38.13 Million | ▲ +4.9% |
| 2013 | -0.21x | $-4.92 Million | $23.37 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.